Table 3 Oncological outcomes
Reference | N | Stades | Survival outcomes | Treatment | Rates |
|---|---|---|---|---|---|
Burns et al. [12] | 18 | cT1 (18) | 3-years DFS | Surgery (8) | 89.0 |
Radiotherapy (8) | 85.3 | ||||
Ferlito and Recher [26] | 77 | cT1-T4 | 5-years metastasis | Surgery and RT (6) | 0 |
5-years local control rate | Surgery (60) | 96.7 | |||
Radiotherapy (1) | 0 | ||||
Surgery + RT (6) | 66.4 | ||||
Blakeslee et al. [14] | 12 | cT1 (12) | 3-years DSS | Surgery (12) | 100 |
3-years Recurrence | 0 | ||||
Lundgren et al. [8] | 44 | cT1 (21) | 82.2-months RFS | Surgery (16) | 75.0 |
cT2 (18) | Radiotherapy (28) | 43.0 | |||
cT3 (3) | |||||
cT4 (2) | |||||
Sllamniku et al. [15] | 15 | cT1 (7) | 5-years OS | Surgery (15) | 62.5 |
cT2 (3) | |||||
cT3 (5) | |||||
Hagen et al. [16] | 12 | cT1 (6) | 8-years RFS | Surgery (10) | 80.0 |
cT2 (3) | Radiotherapy (2) | 100 | |||
cT3 (4) | 6-years DFS | Surgery and RT | 83.0 | ||
6-years metastasis rate | Radiotherapy (2) | 50 | |||
Surgery (10) | 0 | ||||
Fliss et al. [17] | 29 | cT1 (12) | 16-months OS | Surgery (6) | 83.3 |
cT2 (9) | 62-months OS | Radiotherapy (16) | 62.5 | ||
cT3 (1) | 40-months recurrence | Surgery (6) | 0 | ||
Unknown (7) | Radiotherapy (16) | 37.0 | |||
Longarela Herrero et al. [18] | 11 | cT1-T2 | 5-years OS | Surgery (11) | 100 |
Huang et al. [24] | 62 | cT1 (19) | 5-years local control rate | Radiotherapy (62) | 66.0 |
cT2 (36) | 10-years local control rate | 64.0 | |||
cT3 (6) | 5-years OS | 87.0 | |||
cT4 (1) | 10-years OS | 64.0 | |||
5-years DSS | 97.0 | ||||
10-years DSS | 95.0 | ||||
Maurizi et al. [19] | 31 | cT1 (15) | 79-months recurrence | Surgery and RT (31) | 23 |
cT2 (10) | 79-months OS | Surgery and RT (31) | 93.3 | ||
cT3 (6) | Surgery (23) | 100 | |||
Surgery + RT (7) | 71.4 | ||||
Damm et al. [20] | 21 | cT1 (14) | 52-months DFS | Surgery (21) | 85.7 |
cT2 (7) | 52-months recurrence | 5 | |||
McCaffrey et al. [21] | 52 | cT1 (33) | 5-years OS | Surgery and RT (52) | 96.1 |
cT2 (5) | 5-years RFS | 71.0 | |||
cT3 (12) | |||||
cT4 (2) | |||||
Strojan et al. [22] | 30 | cT1 (4) | 5-years OS | Surgery, RT and CRT (30) | 75.0 |
cT2 (11) | 5-years DSS | 100 | |||
cT3 (12) | 5-years LFFS | 97.0 | |||
cT4 (3) | |||||
Hod et al. [23] | 18 | cT1 (18) | 48-months recurrence rate | Surgery (13) | 7.7 |
Surgery + RT (5) | 80.0 | ||||
Dubal et al. [3] | 452 | cT1 (92) | 1-year DFS and RS | Surgery and RT (452) | 97.5—98.1 |
cT2 (53) | 5-years DFS and RS | Surgery and RT (392) | 88.0—85.5 | ||
cT3 (21) | 10-years DFS and RS | Surgery and RT (339) | 77.4—74.2 | ||
cT4 (6) | 5-years DSS | Surgery (292) | 90.2 | ||
Radiotherapy (48) | 80.6 | ||||
Jayakrishnan et al. [25] | 396 | cT1 (217) | 5-years OS | Surgery (286) | 79.0 |
cT2 (186) | Radiotherapy (110) | 67.0 |